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The incidence of breast cancer has increased in Western countries
since the 1980s. Breast cancer represents the most common cause
of cancer death in women. Identifying factors that may influence
susceptibility to this disease is an important challenge. Several risk
factors are well known, such as age at first pregnancy, age at start
of puberty, age at menarche, duration of lactation (Franceschi et al,
1990), body mass index (Katoh et al, 1994) and diet (Hunter and
Willet, 1994). Epidemiological studies have also shown the role of
a family history as a powerful predictor for breast cancer risk
(Claus, 1994). Genetic factors are believed to account for at least
5% of all cases of breast cancer (Easton et al, 1993). Rapid
developments in molecular genetics have allowed the identifica-
tion of two major breast cancer susceptibility genes involved in
early-onset breast cancer families (Miki et al, 1994; Wooster et al,
1995). However, recent data collected worldwide (Szabo and
King, 1997) suggest that germinal mutations of either BRCA1 or
BRCA2 are observed at a lower rate than expected in breast or
breast–ovarian cancer families. Therefore, other susceptibility
genes have yet to be identified.
It is well known that up to 80% of human cancers arise as a conse-
quence of environmental exposure (Doll and Peto, 1981). Many
compounds in their native or metabolized forms are able to affect
DNA integrity and may lead to cancer if exposure persists.
Accumulation of these genetic alterations, together with spontaneous
DNA replication errors, not corrected by DNA repair systems, could
lead to development and/or progression of primary breast cancers.
The first line of defence is provided by the ability to metabolize
and detoxify xenobiotic toxins (Smith et al, 1995). Inhibition of
phase I enzymes, which are involved in carcinogen activation,
and/or activation of phase II enzymes, which normally play a
detoxifying role, should be able to protect cells against carcino-
genic effects of genotoxins. Therefore, deletion or mutation of the
genes coding for these phase II enzymes may be responsible for
individual or even inherited susceptibility to environmental or
endogenous factors, thus predisposing their carriers to the devel-
opment of cancer in the presence of such genomic insults.
Glutathione S-transferase (GST) genes encode a family of
detoxifying phase II enzymes (EC 2.5.1.18), catalysing the conju-
gation of glutathione to electrophilic compounds. Substrates
include exogenous carcinogens and products of oxidative stress. A
member of the GST gene superfamily, GSTM1, has been mapped
to 1p13 (Pearson et al, 1993). Three different alleles of this gene
have been identified: GSTM1* A; GSTM1* B, which differs from
the A allele by a point mutation in exon 7, thus introducing a HaeII
restriction site in the gene sequence (Fryer et al, 1993); and
GSTM1* 0, which represents the absence of its allele (Seidegard et
al, 1988). When this deletion is homozygous, it confers the null
genotype on the carrier (Seidegard and Pero, 1988; Seidegard et al,
1988; Strange et al, 1991). The frequency of the null genotype
varies from 30% to 80%, depending on the ethnic group studied
(Lin et al, 1994). The protein encoded by this gene primarily
catalyses the detoxification of alkyl and polycyclic aromatic
hydrocarbons (PAHs), intermediate forms of many carcinogens,
specifically metabolically generated epoxide intermediates of
benzo(a)pyrene. Furthermore, the protein is also able to reduce
some superoxides (Smith et al, 1995) and the products of oxidative
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stress, such as DNA hydroperoxides. Previous studies have
demonstrated that subjects with the GSTM1 null genotype or
phenotype have an increased risk of developing several cancers,
notably lung cancer in heavy smokers (Seidegard et al, 1986;
Seidegard et al, 1990; Nazart-Stewart, 1993). However, because of
the lack of consensus (Strange et al, 1991), and the existence of
ethnic differences in the GSTM1 genotype distribution (Lin et al,
1994), each type of cancer must be investigated in the context of a
specific ethnic background before using the GSTM1 0 genotype as
a biomarker to define high-risk subjects.
Several studies have investigated the GSTM1 null genotype
prevalence in case–control studies of breast cancer without demon-
strating a statistically significant difference between cases and
controls. Zhong et al (1993) compared 225 controls and 197 breast
cancer patients; Harada et al (1992) studied 84 controls and 65
patients. Ambrosone et al (1995) restricted their study to post-
menopausal women: they compared 212 Caucasian patients and 282
community controls and discovered a trend towards an increased
breast cancer risk among GSTM1 null post-menopausal women
under 58 years of age [odds ratio (OR) = 2.44]. Paradiso et al (1994)
did not detect a difference for the null phenotype frequency among
63 breast cancer patients and 45 healthy patients. In the current
study on a broad series of 361 prevalent breast cancers and 437
female controls, we investigated the influence of the GSTM1 null
genotype and of the different GSTM1 alleles for susceptibility to
breast cancer. Allelism at these loci was studied using polymerase
chain reaction (PCR) for GSTM1 null genotype determination and
allele-specific PCR for A and B allele identification.
MATERIALS AND METHODS
Study population and sample collection
A total of 361 female Caucasian patients from the west of France
bearing histologically proven breast cancer (mean age 51 ± 10,
range 26–80), were recruited in the René Gauducheau Cancer
Centre in Nantes between 1993 and 1996. Control blood samples
were obtained from 437 community Caucasian females without
any neoplasic disease (mean age 47 ± 13, range 18–101). The
protocol had received local ethics committee approval.
Blood (10 ml) was collected in EDTA from all patients. Red
cells were lysed after two washes of 1 h each with cold Tris–EDTA
buffer (20 mM Tris, 5 mM EDTA). DNA was extracted using a
standard phenol–chloroform extraction procedure after proteolysis
with proteinase K as described by Sambrook et al. (1989).
PCR for identification of GSTM1 null and non-null
genotypes
A 273-bp fragment was amplified by multiplex PCR with GSTM1
primers for exons 4–5 as described by Comstock et al (1990)
together with a 350-bp sequence of the prostate-specific antigen
gene (PSA) as internal control using Moreno’s primer sequences
(Moreno et al, 1992). DNA templates were amplified in a total
volume of 25 ml containing 180 mM of each dNTP, 0.6 mM of each
primer, 2.5 mM magnesium chloride, 20 mM Tris-HCl pH 8.55,
16 mM ammonium sulphate, 150 mg ml–1 bovine serum albumin
(BSA) and 0.65 units of Biotaq DNA polymerase (Bioprobe, Paris,
France). After initial denaturation at 94°C (5 min), 25 cycles of
amplification, 56°C (30 s), 72°C (1 min) and 94°C (1 min) were
performed followed by one cycle at 56°C (30 s) and 72°C (7 min).
PCR products were run on 3% agarose gels stained with ethidium
bromide. Determination of the homo- or hemizygote presence of
the gene was achieved by comparing the intensities of the PCR
products of the GSTM1 gene with those of the PSA gene (Figure
1). Mostly, it was possible to show the presence of zero, one or two
alleles by direct analysis on the gel, as four samples were system-
atically introduced as positive controls in each PCR, two GSTM1
hemizygotes, GSTM1* A/GSTM1* 0 and GSTM1* B/GSTM1* 0,
and two homozygotes, GSTM1* A/GSTM1* A and GSTM1*
B/GSTM1* B. Each DNA template was amplified in at least two
different PCRs.
The ratio between the GSTM1 and PSA band intensities was
computed by densitometric measurement on the Polaroid negative
photograph of the gel. A ratio of 0.3–0.7 was considered to
correspond to GSTM1 hemizygosity and 0.7–1.2 to GSTM1
homozygosity or heterozygosity (Figure 2).
Linearity of the internal standard amplification with DNA
concentrations has been tested using quantities ranging from 10 to
2000 ng. A hemizygous DNA sample and a sample containing two
alleles were amplified. The reproducibility of the results was
investigated with a hemizygous sample and a sample containing
two alleles. Each of them were amplified in the same PCR and in
different PCRs.
Validation of the results was performed on 45 non-null samples,
randomly selected, each amplified in at least two separate PCRs.
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Figure 1 PCR for identification of GSTM1 null and non-null genotypes. Agarose gel of PCR products showing the 273-bp DNA fragment amplified from
GSTM1 with a 350-bp sequence from the PSA gene as internal control. From left to right: lanes 1 and 6, hemizygote subjects; lanes 2, 3, 4 and 5, GSTM1 null
subjects; lane 7, homo- or heterozygous subject; lane 8, DNA size marker (1-kb ladder). Note that the intensity of the GSTM1 band amplified from the
hemizygotes is inferior to that of the internal PSA control band, in contrast to the homo-heterozygote, in whom the intensity is about equal. The GSTM1 band is
absent in the GSTM1 null subjects, without loss of the PSA band348 J Charrier et al
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Finally, the results described in this paper were obtained using
100 ng of DNA template for each sample.
PCR for identification of GSTM1 alleles A and B
Identification of one of the GSTM1 genotypes – GSTM1* A /
GSTM1* B, GSTM1* A / GSTM1* A, GSTM1* B / GSTM1* B,
GSTM1* A / GSTM1* 0 or GSTM1*B / GSTM1*0 – was achieved
by PCR amplification of the homozygotes, heterozygotes and
hemizygotes for GSTM1 DNA using the method previously
described by Fryer et al (1993a). An allele-specific PCR was
performed as follows: 300 ng of genomic DNA was amplified in a
volume of 50 ml containing 1.5 mM magnesium chloride, 200 mM
of each dNTP, 600 nM of each primer, 1.5 units of Amplitaq
(Perkin Elmer Cetus, Paris, France) and Amplitaq buffer. DNA
from patients positive for GSTM1 alleles resulted in a 132-bp frag-
ment. b-Globin primers (600 nM) were added as control for ampli-
fication and resulted in the production of a 299-bp DNA fragment.
After initial denaturation at 94°C (5 min), 30 cycles of 94°C
(45 s), 57°C (1 min) and 72°C (1.5 min) were performed.
Confirmation of the presence of the A or B allele was accomplished
by restriction of 20 ml of the PCR product with HaeII (4 h at 37°C).
Migration on 4% agarose gels allowed the distinction between the
non-digested B allele (132 bp) and the digested A allele (112 bp).
The accuracy of our methods of identifying allele number and
distinguishing hemizygosity for A or B alleles was checked by
studying the transmission of those alleles among a set of five
cancer families, recruited with informed consent during genetic
counselling.
Statistical analysis
Odds ratios (ORs) and 95% confidence intervals (CIs) were calcu-
lated for the association of the GSTM1 null genotype with breast
cancer using the Miettinen (1976) calculation method; the hypoth-
esized high-risk category (i.e. GSTM1 deleted) served as reference
category for the model.
Statistical significance was assessed by using the c2 test. The
observed distribution within breast cancer patients was compared
with the observed distribution within the controls according to four
different criteria: null and non-null genotype, number of alleles (0,
1 or 2), distribution of the A, 0, B and AB allelotypes, and distrib-
ution of the six different genotypes: GSTM1* A / GSTM1* 0,
GSTM1* A / GSTM1* A, GSTM1* B / GSTM1* 0, GSTM1* B /
GSTM1* B, GSTM1* A / GSTM1* B and GSTM1* 0 / GSTM1* 0.
Unstratified comparison was performed, as well as comparison
within strata of age at diagnosis for breast cancer patients or age at
sampling for controls. Two groups of subjects were defined: under
50 years of age (< 50 age group) and 50 years of age and over (³ 50
age group). When one of the calculated values was less than 5 on
A
B
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Figure 2 Quantification of GSTM1 homo- or hemizygosity. The ratio between the GSTM1 and PSA band intensities was quantified by densitometric
measurement of the Polaroid photograph of the gel. A ratio of 0.3–0.7 was considered to correspond to hemizygosity (A) and 0.8–1.2 to homozygosity (B)Glutathione S-transferase M1 allelopolymorphism and breast cancer 349
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the contingency tables, the Fisher exact test was used. Statistical
analyses were performed using the Statview package, version 4.02.
RESULTS
PCR linearity
Linearity of PCR co-amplification of GSTM1 and PSA product
was checked over a 10–2000 ng range of DNA template
quantities.
For the hemizygote sample, a good linearity was obtained
between 10 and 300 ng with a correlation coefficient R2 = 0.86.
When the sample contained two alleles, very good linearity was
observed between 10 and 300 ng with a correlation coefficient
R2 = 0.98 (data not shown).
PCR reproducibility
Good inter- and intra-assay reproducibility for allele number
determination was observed for samples amplified ten times in the
same PCR and in ten different PCRs for a one-allele (i.e. hemizy-
gous) sample; the computed ratios between GSTM1 band and PSA
band intensities were, respectively, 0.62 ± 0.05 and 0.63 ± 0.06. A
sample containing two alleles was amplified seven times in the
same PCR and in nine different PCRs, resulting ratios were
respectively 0.99 ± 0.07 and 0.98 ± 0.09 (data not shown).
Quantitative PCR results
Among the non-null samples, 45 were selected at random to
undergo densitometric measurement. PCRs used for quantification
on these samples were repeated at least twice (mean number of
PCRs 2.8 ± 1.5, range 2–9). By direct comparison, on the
electrophoresis gel, 26 subjects were determined as carrying one
allele, so they were called hemizygous for GSTM1. Nineteen
subjects had two alleles. In those cases, further identification with
a mutated allele-specific amplification (MASA) PCR was needed
to distinguish between the GSTM1* A and the GSTM1* B alleles
and to conclude if they were homo- or heterozygous for those
alleles.
Densitometric measurement of GSTM1 band intensity
compared with PSA band intensity gave an average ratio of
absorbance equal to 0.59 ± 0.07 for the one-allele samples (range
0.40–0.65) and 0.94 ± 0.09 for the two-allele samples (range
0.80–1.18).
These results were in complete accordance with results obtained
on the same samples by direct comparison on the gel.
Population mean age in null and non-null genotypes
No statistically significant difference in mean age according to
null and non-null status was found within the control subjects or
breast cancer patients in our study. In the control group, mean age
Table 1 Distribution of null and non-null genotypes and of allele numbers in subjects aged under 50 and in subjects aged 50 years old and over
Subgroups Patients Controls OR 95% CI c2 d.f.c P-value
n (%) n (%)
Whole group 361 437
GSTM1
Null (no alleles) 201 (55.7) 224 (51.3) 1.37 d.f. = 1 0.22 NSa
Non-null 160 (44.3) 213 (48.7) 0.84 (0.63–1.11)
GSTM1
Null (no alleles) 201 (55.7) 224 (51.3) 1.71 d.f. = 2 0.43 NSa
One allele 139 (38.5) 182 (41.6) 0.85 (0.64–1.14)
Two alleles 21 (5.8) 31 (7.1) 0.75 (0.42–1.35)
< 50 age group 226 330
GSTM1
Null (no alleles) 120 (53.1) 178 (53.9) 0.012 d.f. = 1 0.86 NS
Non-null 106 (46.9) 152 (46.1) 1.03 (0.74–1.45)
GSTM1
Null (no alleles) 120 (53.1) 178 (53.9) 1.81 d.f. = 2 0.40 NS
One allele 93 (41.1) 124 (37.6) 1.11 (0.78–1.59)
Two alleles 13 (5.8) 28 (8.5) 0.69 (0.34–1.38)
³ 50 age group 135 107
GSTM1
Null (no alleles) 81 (60.0) 46 (43.0) 1.99d (1.19–3.32)e 6.26 d.f. = 1 0.009 S*b
Non-null 54 (40.0) 61 (57.0) 0.50 (0.30–0.84)
GSTM1
Null (no alleles) 81 (60.0) 46 (43.0) 10.27 d.f. = 2 0.006 S*
One allele 46 (34.1) 58 (54.2) 0.45 (0.27–0.76) 8.06 d.f. = 1 0.003 S*
Two alleles 8 (5.9) 3 (2.8) 1.51 (0.39–5.94) not available
GSTM1 0 and GSTM1 non-null genotype frequencies in the whole population and within the subgroups of patients and controls were compared according to
age. No significant difference was observed between patients and controls in the whole population; the null genotype was significantly predominant in the group
of patients aged 50 years old and over compared with the same population of controls. Comparison between the number of GSTM1 alleles in patients and
controls in the whole population and within the different subgroups of age is detailed. No significant difference was observed between patients and controls in
the whole population for breast cancer risk; hemizygotes were predominant in the control population aged 50 and over. aNS, non-significant; bS* statistically
significant; cdf, degrees of freedom; dOR calculated with the lowest risk GSTM1 non-null as reference; econfidence interval.350 J Charrier et al
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was 65.1 years in null and 65.2 years in non-null subjects ³ 50
years of age (P = 0.50) and 42.1 years in null and 41.5 years in
non-null subjects <50 years of age (P = 0.94).
In our breast cancer population, mean age was 61.9 years in null
and 63.3 years in non-null patients ³50 years of age (P = 0.67) and
43.9 years in null and 45.3 years in non-null patients <50 years of
age (P = 0.26).
Distribution of null and non-null genotypes
Of the 437 female controls, 51.3% had the GSTM1 null genotype,
7.1% had two alleles and 41.6% were hemizygous within this
group (Table 1). The null genotype was more frequent in the < 50
age subgroup (53.9%) than in the ³ 50 age subgroup, in which the
observed frequency was only 43%. This 10.9% difference (53.9%
vs 43%) was statistically significant (P = 0.05).
Of 361 breast cancer patients, 55.7% were GSTM1 null, 5.8%
had two alleles and 38.5% were hemizygous (Table 1). In contrast
to the control group, the null genotype was less frequent in the
< 50 age subgroup (53.1%) than in the ³ 50 age subgroup, in which
its frequency reached 60%. However, the 6.9% observed (60% vs
53.1%) difference was not statistically significant (P = 0.23).
There was no significant difference when we compared the
whole affected and control groups or the < 50 age groups for null
and non-null genotype distribution. However, a statistically signif-
icant difference was observed in the ³ 50 age subgroup (OR =
1.99; 95% CI 1.19–3.32; P = 0.009; Table 1) with a clear pre-
dominance of the null genotype in the patient group (60%)
compared with the control group (43%) (Table 1).
Distribution of GSTM1 allele number
Within the total population, most of the subjects had either no or
one allele of GSTM1 (94.2% of the subjects < 50 years of age and
94.1% of the subjects ³ 50 years of age). In this total population, as
well as in the < 50 age group, the number of alleles was not
significantly different between patients and controls (P = 0.43 and
P = 0.86 respectively).
Table 2 Distribution of different GSTM1 genotypes in subjects aged under 50 and in subjects aged 50 years and over
Subgroups of Patients Controls OR 95% CI c2 d.f.c P-value
population N n (%) n (%)
Whole group 361 437
Null 201 (55.7) 224 (51.3) 2.96 d.f. = 3 0.39 NS
A 87 (24.1) 128 (29.3) 0.76 (0.54–1.06)
B 59 (16.3) 71 (16.2) 0.93 (0.62–1.37)
A/B 14 (3.9) 14 (3.2) 1.11 (0.52–2.39)
Null 201 (55.7) 224 (51.3) 4.39 d.f. = 5 0.49 NSa
82 (22.7) 117 (26.8) 0.78 (0.56–1.10)
5 (1.4) 11 (2.5) 0.91 (0.18–1.46)
57 (15.8) 66 (15.1) 0.96 (0.64–1.44)
2 (0.5) 5 (1.1) not available
A/B 14 (3.9) 14 (3.2) 1.11 (0.52–2.39)
< 50 age group 226 330
Null 120 (53.1) 178 (54.0) 0.76 d.f. = 3 0.85 NS
A 57 (25.2) 89 (27.0) 0.95 (0.63–1.42)
B 41 (18.1) 51 (15.4) 1.19 (0.74–1.91)
A/B 8 (3.5) 12 (3.6) 0.99 (0.39–2.49)
Null 120 (53.1) 178 (54.0) 3.89 d.f. = 5 0.56 NS
A/0 53 (23.5) 78 (23.6) 1.01 (0.66–1.53)
A/A 4 (1.8) 11 (3.3) 0.54 (0.17–1.71)
B/0 40 (17.7) 46 (13.9) 1.29 (0.81–2.09)
B/B 1 (0.4) 5 (1.5) not available
A/B 8 (3.5) 12 (3.6) 0.99 (0.39–2.49)
³ 50 age group 135 107
Null 81 (60.0) 46 (43.0) 9.81 d.f. = 3 0.02 S*b
A 30 (22.2) 39 (36.4) 0.44 (0.24–0.79)
B 18 (13.3) 20 (18.7) 0.51 (0.25–1.06)
A/B 6 (4.4) 2 (1.9) not available
Null 81 (60.0) 46 (43.0) 12.28 d.f. = 5 0.03 S*
A/0 29 (21.5) 39 (36.4) 0.42 (0.23–0.77)
A/A 1 (0.7) 0 (0.0) not available
B/0 17 (12.6) 20 (18.7) 0.48 (0.23–1.01)
B/B 1 (0.7) 0 (0.0) not available
A/B 6 (4.4) 2 (1.9) 1.70 (0.34–8.64)
Comparison between GSTM1 alleles A, B, AB and 0 in patients and controls in the whole population and in the different subgroups according to age. No
significant difference was observed between patients and controls in the whole population; the null genotype and the AB genotype were predominant in the
group of patients age 50 and over compared with the same population of controls. In contrast, the A allele was predominant in the control population aged 50
and over. The A/0 genotype was predominant in the control population of 50 years old and over. aNS, non-significant; bS*, statistically significant; cd.f., degrees
of freedom.Glutathione S-transferase M1 allelopolymorphism and breast cancer 351
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However, in the ³ 50 age group, people with one allele were
significantly more common in the control group than in the patient
group (P = 0.006) (Table 1). Moreover, in this subgroup, cancer
risk related to the presence of one allele was significantly decreased
in hemizygous subjects compared with null subjects (OR = 0.45;
95% CI 0.27–0.76; P = 0.003) (Table 2). This was not observed
when we compared subjects who had two alleles with null subjects.
The significance of this last comparison was not calculated because
of the small size of the two allele groups (Table 2).
Thus, the risk of breast cancer occurrence was reduced in
hemizygous subjects ³ 50 years of age. However, the role of the
presence of two alleles in determination of the breast cancer risk
could not be examined owing to the small size of this subgroup.
Distribution of A and B allelotypes in non-null subjects
Among non-null subjects, the A allelotypes were more frequent, B
allelotypes were less frequent and A/B was rare without any statis-
tically significant difference in distribution between cases and
controls (Table 2). Surprisingly, in the ³ 50 age control group, the
A allelotypes were more prominent than in the ³ 50 age patient
group; the B allelotypes were slightly over-represented in the ³ 50
age control group and A/B carriers were less frequent. This differ-
ence in allelotype distribution was statistically significant (P =
0.02) (Table 2). Moreover, the A/0 and B/0 genotypes were over-
represented in the ³ 50 age control group when compared with the
³ 50 age patient group, with a statistically significant difference
(P = 0.03). The A/0 genotype and, to a lesser extent, the B/0
genotype were responsible for a decreased risk of breast cancer
in the ³ 50 age group (OR = 0.42, 95% CI, 0.23–0.77, and
OR = 0.48, 95% CI 0.23–1.01, respectively) (Table 2).
DISCUSSION
Although the GSTM1 null genotype in our study was more
frequent in breast cancer cases than in controls, this difference
does not reach a statistical significance in the overall population.
This is consistent with results previously reported for smaller
groups by Harada et al (1992), Zhong et al (1993) or Paradiso et al
(1994) comparing null and non-null genotypes.
As we cannot take into account the precise hormonal status of
women in our series, because these data were not recorded in most
of our controls and were missing for some of the cancer patients,
we examined the influence of allelism at the GSTM1 locus on
breast cancer susceptibility according to subsequent subcategories:
(1) women < 50 years of age and (2) women ³ 50 years of age.
This subdivision best approximates the division according to the
menopausal status.
Within individuals aged 50 years old and over, we identified a
statistically significant increase in null genotype frequency in
cancer patients (P = 0.009, OR = 1.98). Ambrosone et al (1995)
did not find any increased breast cancer risk linked to the GSTM1
null genotype. However, they detected a trend to an elevated, but
not statistically significantly increased, risk when they studied
young post-menopausal patients (under 58 years old). The discrep-
ancy between their results and ours in women 50 years old and
over may be due to a difference in recruited population character-
istics: in their study, cases with the null genotype were signifi-
cantly younger than those with the non-null genotype; this was not
the case in our series. Taken together, these results suggested a
putative role of GSTM1 in breast cancer susceptibility in the post-
menopausal group. Our data do suggest a role for the null geno-
type in late-onset breast cancer susceptibility with an OR of 1.99
(95% CI 1.19–3.32).
In the < 50 years of age breast cancer-affected population, other
genes, such as the two major predisposition genes, BRCA1 and
BRCA2 are known to play the most important role in breast cancer
susceptibility (Miki et al, 1995; Wooster et al, 1995; Rebbeck et al,
1996). However, those genes are not sufficient to explain breast
cancer susceptibility in every cancer-prone family (Easton et al,
1997). Our current data, as well as previous results, do not suggest
any role of GSTM1 in the early onset of breast cancer.
The null genotype was 10.9% less frequent in the ³ 50 age
controls than in the < 50 age control subgroups and 6.9% more
frequent in the ³ 50 age patients than in the patients in the < 50 age
subgroup (Table 1). These data suggest that some of the GSTM1
null subjects who did not develop breast cancer may have died
from neoplastic diseases other than breast cancer, or from various
other pathologies. The role of the null genotype in diseases such as
inflammatory diseases has already been reported, for example in
patients suffering from Crohn’s disease (Duncan et al, 1995) or
systemic lupus erythematosus with a Ro+/La– autoantibody profile
(Ollier et al, 1996).
We also studied non-null subjects for the presence of either A or
B alleles of the GSTM1 gene and distinguished between homozy-
gotes A/A, B/B, heterozygotes A/B and hemizygotes A/0 and B/0.
This allowed us to investigate the putative protective role of these
particular alleles, as well as a dosage effect of these alleles.
In the ³ 50 age group, the A allelotype was more prominent in
the control group than in the patient population (Table 2); a
slightly higher incidence of the B allelotype was also observed in
the control group. Moreover, a higher incidence of A/0 and B/0
genotypes was found in the control group (Table 2). The corre-
sponding OR suggested a protective effect of a single allele in
these subsets of the population. Interestingly, this protective effect
was not observed with the A/B genotype. However, this subgroup
is too small to yield meaningful statistics. It will be of interest to
investigate the differential role of the A/A vs the A/0 genotype,
and of the B/B vs the B/0 genotype, in order to determine if a
different dosage of these alleles is playing a role in breast cancer
susceptibility. However, the number of subjects in our study was
not sufficient to identify statistically significant differences, and
the current study will have to be extended to investigate this
hypothesis.
Distinguishing between the A and B alleles seems to be inter-
esting because their role may be different: Fryer et al (1993b)
demonstrated that the B allele confers better protection against
pituitary adenomas than does the A allele, and Duncan et al (1995)
also observed a putative protective effect of the B allele in Crohn’s
disease. Heagerty et al (1994) and Yengi et al (1996) have shown a
protective effect of the GSTM1*A and GSTM1* B alleles in cuta-
neous basal cell carcinoma but did not distinguish (A/A) and (B/B)
from respectively (A/0) and (B/0), so the influence of the allele
number cannot be assessed by their study.
Like previous studies, our data failed to find a statistically
significant prevalence of the GSTM1 null genotype in breast
cancer when we analysed the complete population. The effect of
the null genotype could be insufficient by itself to favour cancer
development. Studying other susceptibility genes could be helpful
to define a ‘high-risk haplotype’.
The effect of interaction of GSTM1 with other polymorphic
genes encoding detoxifying enzymes is of interest. For example,352 J Charrier et al
British Journal of Cancer (1999) 79(2), 346–353 © Cancer Research Campaign 1999
the Cyp1A1 allele was found to increase the risk of lung cancer in
Japanese GSTM1 null subjects (Nakachi et al, 1993).
We cannot exclude the existence of interactions between GSTM1
and major predisposition genes. Such interactions have already
been demonstrated for other genes such as HRAS1. Phelan et al
(1996) showed that carriers of BRCA1 mutations, harbouring one or
two rare alleles of HRAS1, had an ovarian cancer risk that was 2.11-
fold higher than that of those carrying common alleles of HRAS1.
Environmental factors or diet intake may increase the occur-
rence of a malignant phenotype in GSTM1 null subjects. This was
observed for lung cancer where frequent smoking (Kihara et al,
1994) or low vitamin C consumption (Garcia-Closas et al, 1995)
results in a higher cancer risk in the GSTM1 0 population than in
the non-null population.
In conclusion, we hypothesize, based on our current data, that
long-term exposure to environmental or endogenous carcinogenic
factors could favour breast cancer development in the ³ 50 age
group in previously healthy patients bearing the null genotype.
Moreover, the null genotype could predispose to other pathologies.
That is why we propose that the null genotype may be responsible
for a lower life expectancy. The follow-up, in a longitudinal study,
of our control group, to register each pathology developed by null
and non-null subjects will allow us to investigate this hypothesis.
Integration of germline DNA genotyping for polymorphisms of
different carcinogen-metabolizing enzymes and information about
dietary habits, lifestyle and family history in a prospective
case–control study will be necessary to elucidate further the role of
interaction between different genes for carcinogen-metabolizing
enzymes and between these genes and environmental factors.
ABBREVIATIONS
GST, glutathione S-transferase; PCR, polymerase chain reaction;
MASA, mutated allele specific amplification; PAH, polyaromatic
hydrocarbon; OR, odds-ratio; CI, confidence interval
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